Tom Frohlich, Jade Biosciences CEO
Q&A: Jade CEO talks about reverse merger and IgAN drugs
This week, biotech builder Paragon Therapeutics took two of its portfolio companies public through reverse mergers — Crescent Biopharma and now
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
